Myelitis, Transverse: Clinical Trials

11 trials for Myelitis, Transverse, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 3 unknown, 1 active not recruiting, 1 not yet recruiting. 11 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 411Completed 4, Unknown 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1

Follow Myelitis, Transverse: new trials by email Literature Review of Myelitis, Transverse trials Research Report on Myelitis, Transverse

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
Crisugabalin, Placebo+Crisugabalin - Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain
Phase 4Not yet recruitingTang-Du Hospital1102026-06-152026-07-13
Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
Eculizumab+IVMP, IVIG+IVMP, IVMP - Neuromyelitis Optica Spectrum Disorder Attack
Phase 4RecruitingChinese PLA General Hospital2002026-02-012026-03-12
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Blood tests, Inebilizumab - Neuromyelitis Optica Spectrum Disorder
Phase 4Active not recruitingAmgen322024-04-022025-11-21
A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
Inebilizumab - Neuromyelitis Optica Spectrum Disorders
Phase 4UnknownHansoh BioMedical R&D Company332024-02-252024-01-18
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
Satralizumab 120 mg - Neuromyelitis Optica Spectrum Disorder, NMOSD
Phase 4TerminatedHoffmann-La Roche42022-08-022025-01-22
Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder
Azathioprine - NMO Spectrum Disorder, Azathioprine Adverse Reaction
Phase 4CompletedFirst Affiliated Hospital of Guangxi Medical University632020-01-012023-06-09
Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients
Mycophenolate mofetil, Prednisone - Neuromyelitis Optica Spectrum Disorders, Mycophenolate Mofetil
Phase 4UnknownThird Affiliated Hospital, Sun Yat-Sen University1002016-01-012016-06-22
Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE)
Rituximab - Neuromyelitis Optica Spectrum Disorder
Phase 4CompletedTang-Du Hospital1082014-04-012020-10-19
Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
Mitoxantrone - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorders
Phase 4UnknownXuanwu Hospital, Beijing502009-03-012013-12-27
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
Mitoxantrone - Neuromyelitis Optica, Myelitis, Transverse
Phase 4CompletedState University of New York at Buffalo52001-08-012020-12-28
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
interferon beta 1a 30 ug IM once weekly - Multiple Sclerosis, Optic Neuritis
Phase 4CompletedBeth Israel Deaconess Medical Center1552001-02-012017-09-06

Narrower conditions

Neuromyelitis Optica (10)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Cerebellar Diseases (1)  ·  Demyelinating Autoimmune Diseases, CNS (1)  ·  Multiple Sclerosis (1)  ·  Neuralgia (1)  ·  Optic Neuritis (1)  ·  Recurrence (1)

Broader conditions

Autoimmune Diseases (11)  ·  Cranial Nerve Diseases (11)  ·  Demyelinating Diseases (11)  ·  Eye Diseases (11)  ·  Immune System Diseases (11)  ·  Nervous System Diseases (11)  ·  Optic Nerve Diseases (11)  ·  Autoimmune Diseases of the Nervous System (10)  ·  Demyelinating Autoimmune Diseases, CNS (10)  ·  Optic Neuritis (10)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Central Nervous System Infections (2)  ·  Infections (2)

Interventions

Mitoxantrone (2)  ·  inebilizumab (2)  ·  Azathioprine (1)  ·  Hematologic Tests (1)  ·  Interferon beta-1a (1)  ·  Mycophenolic Acid (1)  ·  Prednisone (1)  ·  Rituximab (1)  ·  satralizumab (1)

Sponsors

Tang-Du Hospital (2)  ·  Amgen (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Chinese PLA General Hospital (1)  ·  First Affiliated Hospital of Guangxi Medical University (1)  ·  Hansoh BioMedical R&D Company (1)  ·  Hoffmann-La Roche (1)  ·  State University of New York at Buffalo (1)  ·  Third Affiliated Hospital, Sun Yat-Sen University (1)  ·  Xuanwu Hospital, Beijing (1)

Countries

China (6)  ·  United States (4)  ·  South Korea (2)  ·  Canada (1)  ·  Czechia (1)  ·  Hungary (1)  ·  Poland (1)  ·  Thailand (1)  ·  Turkey (Türkiye) (1)

Top investigators

Bianca Weinstock-Guttman, M.D. (1)  ·  Hongzeng Li (1)  ·  Huiqing Dong, Doctor (1)  ·  Jun Guo (1)  ·  Revere P Kinkel, MD (1)  ·  Wei Qiu, Medical PhD (1)  ·  Yulan Tang (1)

Results publications

PMID 16638802, PMID 16831964, PMID 19752302, PMID 25199960, PMID 30258442